298 related articles for article (PubMed ID: 25405932)
1. The epigenetics of prostate cancer diagnosis and prognosis: update on clinical applications.
Blute ML; Damaschke NA; Jarrard DF
Curr Opin Urol; 2015 Jan; 25(1):83-8. PubMed ID: 25405932
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic targets in the diagnosis and treatment of prostate cancer.
Manoharan M; Ramachandran K; Soloway MS; Singal R
Int Braz J Urol; 2007; 33(1):11-8. PubMed ID: 17335593
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic biomarkers in prostate cancer: Current and future uses.
Chiam K; Ricciardelli C; Bianco-Miotto T
Cancer Lett; 2014 Jan; 342(2):248-56. PubMed ID: 22391123
[TBL] [Abstract][Full Text] [Related]
4. Epigenetics in prostate cancer: biologic and clinical relevance.
Jerónimo C; Bastian PJ; Bjartell A; Carbone GM; Catto JW; Clark SJ; Henrique R; Nelson WG; Shariat SF
Eur Urol; 2011 Oct; 60(4):753-66. PubMed ID: 21719191
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic Modifications and Modulators in Prostate Cancer.
Cimadamore A; Gasparrini S; Scarpelli M; Doria A; Mazzucchelli R; Massari F; Cheng L; Lopez-Beltran A; Montironi R
Crit Rev Oncog; 2017; 22(5-6):439-450. PubMed ID: 29604923
[TBL] [Abstract][Full Text] [Related]
6. A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer.
Zhao F; Olkhov-Mitsel E; Kamdar S; Jeyapala R; Garcia J; Hurst R; Hanna MY; Mills R; Tuzova AV; O'Reilly E; Kelly S; Cooper C; ; Brewer D; Perry AS; Clark J; Fleshner N; Bapat B
Clin Epigenetics; 2018 Nov; 10(1):147. PubMed ID: 30470249
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic regulation of EFEMP1 in prostate cancer: biological relevance and clinical potential.
Almeida M; Costa VL; Costa NR; Ramalho-Carvalho J; Baptista T; Ribeiro FR; Paulo P; Teixeira MR; Oliveira J; Lothe RA; Lind GE; Henrique R; Jerónimo C
J Cell Mol Med; 2014 Nov; 18(11):2287-97. PubMed ID: 25211630
[TBL] [Abstract][Full Text] [Related]
8. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.
Dobosy JR; Roberts JL; Fu VX; Jarrard DF
J Urol; 2007 Mar; 177(3):822-31. PubMed ID: 17296351
[TBL] [Abstract][Full Text] [Related]
9. Epigenetics of prostate cancer.
Li LC
Front Biosci; 2007 May; 12():3377-97. PubMed ID: 17485307
[TBL] [Abstract][Full Text] [Related]
10. Comparing diagnostic and prognostic performance of two-gene promoter methylation panels in tissue biopsies and urines of prostate cancer patients.
Moreira-Barbosa C; Barros-Silva D; Costa-Pinheiro P; Torres-Ferreira J; Constâncio V; Freitas R; Oliveira J; Antunes L; Henrique R; Jerónimo C
Clin Epigenetics; 2018 Oct; 10(1):132. PubMed ID: 30373654
[TBL] [Abstract][Full Text] [Related]
11. Aberrant
Bjerre MT; Strand SH; Nørgaard M; Kristensen H; Rasmussen AK; Mortensen MM; Fredsøe J; Mouritzen P; Ulhøi B; Ørntoft T; Borre M; Sørensen KD
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30866497
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic changes in prostate cancer: implication for diagnosis and treatment.
Li LC; Carroll PR; Dahiya R
J Natl Cancer Inst; 2005 Jan; 97(2):103-15. PubMed ID: 15657340
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers for prostate cancer.
Schiffer E
World J Urol; 2007 Dec; 25(6):557-62. PubMed ID: 17690889
[TBL] [Abstract][Full Text] [Related]
14. Using Genetic and Epigenetic Markers to Improve Differential Diagnosis of Prostate Cancer and Benign Prostatic Hyperplasia by Noninvasive Methods in Mexican Patients.
Sánchez BE; Aguayo A; Martínez B; Rodríguez F; Marmolejo M; Svyryd Y; Luna L; Muñoz LA; Jiménez MA; Sotomayor M; Vargas V F; Mutchinick OM
Clin Genitourin Cancer; 2018 Aug; 16(4):e867-e877. PubMed ID: 29571584
[TBL] [Abstract][Full Text] [Related]
15. GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture.
Jeyapala R; Savio AJ; Olkhov-Mitsel E; Kamdar S; Zhao F; Cuizon C; Liu RSC; Zlotta A; Fleshner N; van der Kwast T; Bapat B
Eur Urol Oncol; 2019 May; 2(3):231-238. PubMed ID: 31200836
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic risk score improves prostate cancer risk assessment.
Van Neste L; Groskopf J; Grizzle WE; Adams GW; DeGuenther MS; Kolettis PN; Bryant JE; Kearney GP; Kearney MC; Van Criekinge W; Gaston SM
Prostate; 2017 Sep; 77(12):1259-1264. PubMed ID: 28762545
[TBL] [Abstract][Full Text] [Related]
17. [Update on the diagnosis of PCa in urine. The current role of urine markers].
Fernandez-Serra A; Casanova-Salas I; Rubio L; Calatrava A; García-Flores M; García-Casado Z; López-Guerrero JA; Rubio-Briones J
Arch Esp Urol; 2015 Apr; 68(3):240-9. PubMed ID: 25948797
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic modifications in prostate cancer.
Ngollo M; Dagdemir A; Karsli-Ceppioglu S; Judes G; Pajon A; Penault-Llorca F; Boiteux JP; Bignon YJ; Guy L; Bernard-Gallon DJ
Epigenomics; 2014; 6(4):415-26. PubMed ID: 25333850
[TBL] [Abstract][Full Text] [Related]
19. Random forest-based modelling to detect biomarkers for prostate cancer progression.
Toth R; Schiffmann H; Hube-Magg C; Büscheck F; Höflmayer D; Weidemann S; Lebok P; Fraune C; Minner S; Schlomm T; Sauter G; Plass C; Assenov Y; Simon R; Meiners J; Gerhäuser C
Clin Epigenetics; 2019 Oct; 11(1):148. PubMed ID: 31640781
[TBL] [Abstract][Full Text] [Related]
20. Epigenetics as a Key Factor in Prostate Cancer.
Enikeeva K; Rafikova G; Sharifyanova Y; Mulyukova D; Vanzin A; Pavlov V
Adv Biol (Weinh); 2024 May; 8(5):e2300520. PubMed ID: 38379272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
